Is Immunomedics, Inc. (IMMU) A Good Stock To Buy?

Page 1 of 2

At Insider Monkey, we pore over the filings of more than 700 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of September 30. In this article, we will use that wealth of knowledge to determine whether or not Immunomedics, Inc. (NASDAQ:IMMU) makes for a good investment right now.

Immunomedics, Inc. (NASDAQ:IMMU) was in 5 hedge funds’ portfolios at the end of the third quarter of 2015. IMMU shareholders have witnessed a decrease in support from the world’s most elite money managers in recent months. There were 9 hedge funds in our database with IMMU holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Oil-Dri Corporation of America (NYSE:ODC), KVH Industries, Inc. (NASDAQ:KVHI), and Cloud Peak Energy Inc. (NYSE:CLD) to gather more data points.

Follow Immunomedics Inc (NASDAQ:IMMU)

Today there are a multitude of signals market participants employ to appraise their stock investments. Two of the less known signals are hedge fund and insider trading signals. We have shown that, historically, those who follow the best picks of the best hedge fund managers can outperform their index-focused peers by a solid amount (see the details here).

With all of this in mind, let’s check out the fresh action surrounding Immunomedics, Inc. (NASDAQ:IMMU).

Hedge fund activity in Immunomedics, Inc. (NASDAQ:IMMU)

At Q3’s end, a total of 5 of the hedge funds tracked by Insider Monkey were long this stock, a change of -44% from the previous quarter. With the smart money’s sentiment swirling, there exists a select group of key hedge fund managers who were upping their holdings significantly (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Samuel Isaly’s OrbiMed Advisors has the most valuable position in Immunomedics, Inc. (NASDAQ:IMMU), worth close to $5.7 million, comprising 0.1% of its total 13F portfolio. Coming in second is Balyasny Asset Management, led by Dmitry Balyasny, holding a $3.4 million position; the fund has less than 0.1% of its 13F portfolio invested in the stock. Another smart money long IMMU is D E Shaw.

Page 1 of 2